Incorporated in 1991, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations across various acute and chronic therapeutic areas and several consumer healthcare products.
In India, the business is active in a number of acute and chronic therapeutic fields, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.
Mankind Pharma has one of the largest distribution networks of medical representatives in the Indian pharmaceutical market. Over 80% of doctors in India prescribed their formulations and has been ranked number 4th in terms of domestic sales during the Financial Year 2022.
The company has earned numerous awards and recognitions and including The Best of Bharat Awards 2022 by exchange4media in the year 2022, and Silver Medal from National Awards for Manufacturing Competitiveness Assessment 2021 instituted by International Research Institute for Manufacturing.
Mankind has a pan-India marketing presence, with a field force of 11,691 medical representatives and 3,561 field managers, as of December 31, 2022. They operate 25 manufacturing facilities across India and had 4,121 manufacturing personnel as of December 31, 2022.
As of December 31, 2022, the Company had a team of over 600 scientists and a dedicated in-house R&D center with four units located in IMT Manesar, Gurugram, Haryana and Thane, Maharashtra.
Mankind Pharma IPO Details
| IPO Date | Apr 25, 2023 to Apr 27, 2023 |
| Listing Date | [.] |
| Face Value | ₹1 per share |
| Price | ₹1026 to ₹1080 per share |
| Lot Size | 13 Shares |
| Total Issue Size | 40,058,844 shares (aggregating up to ₹4,326.36 Cr) |
| Offer for Sale | 40,058,844 shares of ₹1 (aggregating up to ₹4,326.36 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
Mankind Pharma IPO Reservation
| QIB Shares Offered | Not more than 50% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
Mankind Pharma IPO Tentative Timetable
Mankind Pharma IPO opens on Apr 25, 2023, and closes on Apr 27, 2023.
| Event | Tentative Date |
|---|---|
| Opening Date | Apr 25, 2023 |
| Closing Date | Apr 27, 2023 |
| Basis of Allotment | May 3, 2023 |
| Initiation of Refunds | May 4, 2023 |
| Credit of Shares to Demat | May 5, 2023 |
| Listing Date | May 8, 2023 |
| UPI Mandate Confirmation Cut-Off Time | 5.00 PM on the issue closing day |
Mankind Pharma IPO Lot Size
The Mankind Pharma IPO lot size is 13 shares.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 13 | ₹14,040 |
| Retail (Max) | 14 | 182 | ₹196,560 |
| S-HNI (Min) | 15 | 195 | ₹210,600 |
| S-HNI (Max) | 71 | 923 | ₹996,840 |
| B-HNI (Min) | 72 | 936 | ₹1,010,880 |
Mankind Pharma IPO Promoter Holding
Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja Family Trust, Rajeev Juneja Family Trust, and Prem Sheetal Family Trust are the company promoters.
| Pre Issue Share Holding | 79.00% |
| Post Issue Share Holding |
Company Financials(In lakh)
| Period Ended | Total Assets | Total Revenue | Profit After Tax | Net Worth | Reserves and Surplus | Total Borrowing |
|---|---|---|---|---|---|---|
| 31-Mar-20 | 5,073.29 | 5,975.65 | 1,056.15 | 3,485.31 | 3,436.34 | 126.92 |
| 31-Mar-21 | 6,372.63 | 6,385.38 | 1,293.03 | 4,722.00 | 4,674.39 | 234.53 |
| 31-Dec-21 | 8,043.88 | 6,218.29 | 1,260.24 | 5,965.46 | 0.00 | 268.70 |
| 31-Mar-22 | 9,147.74 | 7,977.58 | 1,452.96 | 6,155.23 | 6,106.06 | 868.03 |
| 31-Dec-22 | 9,273.75 | 6,777.82 | 1,015.98 | 7,145.89 | 0.00 | 167.93 |
Key Performance Indicator
| KPI | Values |
|---|---|
| ROCE (%) | 16.58 |
Objects of the Issue
Th company will not receive any proceeds from the Offer and all the Offer Proceeds will be received by the Selling Shareholders, in proportion to the Offered Shares sold by the respective Selling Shareholders as part of the Offer
Mankind Pharma IPO Review (May apply)
[Dilip Davda] A major domestic player in healthcare products is going public with a pure vanilla OFS issue. It is diluting just 10% now. It has shown good financial performance from FY20 to FY22. The setback for 9m of FY23 is due to one-time provisioning for its recent takeovers. Based on recent performance, the issue appears fully priced. It’s a long race horse, hence investors may consider parking funds with a long-term perspective.
Company Contact Information
Mankind Pharma Limited
208, Okhla Industrial Estate
Phase-III,
New Delhi 110020
Phone: +91 11 4684 6700
Email: investors@mankindpharma.com
Website: https://www.mankindpharma.com/
Mankind Pharma IPO Registrar
Kfin Technologies Limited
Phone: 04067162222, 04079611000
Email: mankind.ipo@kfintech.com
Website: https://karisma.kfintech.com/